These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 23072645)

  • 1. The recent progress in RSV vaccine technology.
    Fretzayas A; Papadopoulou A; Kotzia D; Moustaki M
    Recent Pat Antiinfect Drug Discov; 2012 Dec; 7(3):237-41. PubMed ID: 23072645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Respiratory Syncytial Virus Vaccine Vectored by a Stable Chimeric and Replication-Deficient Sendai Virus Protects Mice without Inducing Enhanced Disease.
    Wiegand MA; Gori-Savellini G; Gandolfo C; Papa G; Kaufmann C; Felder E; Ginori A; Disanto MG; Spina D; Cusi MG
    J Virol; 2017 May; 91(10):. PubMed ID: 28250126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The challenges of RSV vaccines. Where do we stand?
    Fretzayas A; Moustaki M
    Recent Pat Antiinfect Drug Discov; 2010 Jun; 5(2):99-107. PubMed ID: 20156180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in and the potential of vaccines for respiratory syncytial virus.
    Jorquera PA; Oakley KE; Tripp RA
    Expert Rev Respir Med; 2013 Aug; 7(4):411-27. PubMed ID: 23964629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The future of respiratory syncytial virus vaccine development.
    Polack FP; Karron RA
    Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S65-73. PubMed ID: 14730272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategic priorities for respiratory syncytial virus (RSV) vaccine development.
    Anderson LJ; Dormitzer PR; Nokes DJ; Rappuoli R; Roca A; Graham BS
    Vaccine; 2013 Apr; 31 Suppl 2(Suppl 2):B209-15. PubMed ID: 23598484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
    Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats.
    Rostad CA; Stobart CC; Gilbert BE; Pickles RJ; Hotard AL; Meng J; Blanco JCG; Moin SM; Graham BS; Piedra PA; Moore ML
    J Virol; 2016 Aug; 90(16):7508-7518. PubMed ID: 27279612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines.
    Wright PF; Karron RA; Belshe RB; Shi JR; Randolph VB; Collins PL; O'Shea AF; Gruber WC; Murphy BR
    Vaccine; 2007 Oct; 25(42):7372-8. PubMed ID: 17868959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Respiratory syncytial virus vaccine: where are we now and what comes next?
    Noor A; Krilov LR
    Expert Opin Biol Ther; 2018 Dec; 18(12):1247-1256. PubMed ID: 30426788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Respiratory syncytial virus vaccines: an update on those in the immediate pipeline.
    Esposito S; Di Pietro G
    Future Microbiol; 2016 Oct; 11():1479-1490. PubMed ID: 27750448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in respiratory syncytial virus vaccine development.
    Kneyber MC; Kimpen JL
    Curr Opin Investig Drugs; 2004 Feb; 5(2):163-70. PubMed ID: 15043390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current progress on development of respiratory syncytial virus vaccine.
    Chang J
    BMB Rep; 2011 Apr; 44(4):232-7. PubMed ID: 21524347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting RSV with vaccines and small molecule drugs.
    Costello HM; Ray WC; Chaiwatpongsakorn S; Peeples ME
    Infect Disord Drug Targets; 2012 Apr; 12(2):110-28. PubMed ID: 22335496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutating the CX3C Motif in the G Protein Should Make a Live Respiratory Syncytial Virus Vaccine Safer and More Effective.
    Boyoglu-Barnum S; Todd SO; Meng J; Barnum TR; Chirkova T; Haynes LM; Jadhao SJ; Tripp RA; Oomens AG; Moore ML; Anderson LJ
    J Virol; 2017 May; 91(10):. PubMed ID: 28275196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccines against human respiratory syncytial virus in clinical trials, where are we now?
    Rossey I; Saelens X
    Expert Rev Vaccines; 2019 Oct; 18(10):1053-1067. PubMed ID: 31587585
    [No Abstract]   [Full Text] [Related]  

  • 17. Respiratory syncytial virus vaccine: a systematic overview with emphasis on respiratory syncytial virus subunit vaccines.
    Simoes EA; Tan DH; Ohlsson A; Sales V; Wang EE
    Vaccine; 2001 Dec; 20(5-6):954-60. PubMed ID: 11738763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parainfluenza Virus 5 Expressing Wild-Type or Prefusion Respiratory Syncytial Virus (RSV) Fusion Protein Protects Mice and Cotton Rats from RSV Challenge.
    Phan SI; Zengel JR; Wei H; Li Z; Wang D; He B
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28747496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.
    Mackow N; Amaro-Carambot E; Liang B; Surman S; Lingemann M; Yang L; Collins PL; Munir S
    J Virol; 2015 Oct; 89(20):10319-32. PubMed ID: 26223633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in the development of subunit-based RSV vaccines.
    Jaberolansar N; Toth I; Young PR; Skwarczynski M
    Expert Rev Vaccines; 2016; 15(1):53-68. PubMed ID: 26506139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.